NeuroMetrix (NASDAQ:NURO) Coverage Initiated by Analysts at StockNews.com

StockNews.com began coverage on shares of NeuroMetrix (NASDAQ:NUROFree Report) in a report issued on Thursday morning. The brokerage issued a sell rating on the medical device company’s stock.

NeuroMetrix Stock Up 3.4 %

NASDAQ NURO opened at $4.54 on Thursday. NeuroMetrix has a 52-week low of $2.66 and a 52-week high of $4.73. The business’s 50-day moving average price is $4.29 and its 200 day moving average price is $4.11. The firm has a market cap of $9.32 million, a P/E ratio of -0.99 and a beta of 2.15.

Institutional Investors Weigh In On NeuroMetrix

A hedge fund recently bought a new stake in NeuroMetrix stock. Renaissance Technologies LLC acquired a new stake in NeuroMetrix, Inc. (NASDAQ:NUROFree Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 11,560 shares of the medical device company’s stock, valued at approximately $46,000. Renaissance Technologies LLC owned approximately 0.57% of NeuroMetrix at the end of the most recent quarter. 19.40% of the stock is owned by institutional investors and hedge funds.

About NeuroMetrix

(Get Free Report)

NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.

Further Reading

Receive News & Ratings for NeuroMetrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroMetrix and related companies with MarketBeat.com's FREE daily email newsletter.